JPMorgan analyst Anupam Rama lowered the firm’s price target on Zai Lab (ZLAB) to $32 from $39 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology space.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
- Zai Lab Advances DLLEVATE Trial In Relapsed Small Cell Lung Cancer
- Zai Lab: Validated Povetacicept Data and China IgAN Opportunity Support Upside and Buy Rating
- Zai Lab Earnings Call: Growth, Pipeline And Volatility
- Zai Lab price target lowered to $37 from $55 at Cantor Fitzgerald
- Zai Lab price target lowered to $47 from $53 at Citi